A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Active, not recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).

Phase 3

UCB Biopharma S.P.R.L.
UCB Biopharma SRL

Antibodies, Monoclonal